Summary & Overview
HCPCS J9333: Injection of rozanolixizumab-noli, 1 mg
HCPCS Level II code J9333 denotes the injection of rozanolixizumab-noli, billed per 1 mg unit. As a biologic therapeutic typically administered in outpatient infusion centers, hospital outpatient departments, or specialty clinics, this code is important for accurately capturing utilization and spend for a targeted monoclonal antibody therapy. National attention on high-cost biologics and specialty drug management makes precise coding and billing for J9333 consequential for payers and providers alike.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise orientation to what the code represents, the expected service settings, and the typical clinical billing context. The publication provides benchmarks and payer coverage summaries where available, highlights common modifiers used in clinical billing workflows, and outlines policy and reimbursement topics relevant to specialty biologic injections. Clinical context about the product and its administration is summarized to assist coding, billing, and revenue cycle teams in aligning documentation and claims submission with payer requirements.
Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, related codes, and per-payer reimbursement rates.
Billing Code Overview
HCPCS Level II code J9333 represents Injection, rozanolixizumab-noli, 1 mg. This code describes a parenteral biologic medication supplied for intravenous or subcutaneous administration for conditions treated with rozanolixizumab-noli.
Service Type: Injection — biologic/monoclonal antibody therapy
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic primary immune thrombocytopenia (ITP) or another approved autoimmune indication for rozanolixizumab-noli who requires intravenous or subcutaneous infusion/injection of the monoclonal antibody formulation. The patient presents to an infusion center, hospital outpatient department, or physician office for administration. Prior to treatment, a clinician (hematologist, immunologist, or trained infusion nurse) reviews recent platelet counts, bleeding history, medication list, and allergy history. Vital signs and weight are obtained; informed consent is confirmed. The drug is prepared by pharmacy in a sterile environment and labeled in milligrams; billing is reported per milligram using J9333 for each 1 mg increment. During the visit, the patient is monitored for infusion-related reactions and vital signs are recorded at baseline and periodically during and after administration. Post-administration observation time varies by institution and patient risk factors. Documentation includes indication, dose in mg, lot number, route, site of administration, start/stop times, pre-medications, and any adverse reactions. Claims may include applicable modifier codes for circumstances such as unusual procedural services, discontinued service, or multiple clinicians involved in care. Typical sites of service: outpatient infusion centers, hospital outpatient departments, and physician offices providing biologic therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|